GLP-1 agonist drugs like Ozempic, and SLGT2 inhibitor drugs like Jardiance have been linked with a lower risk of a second ...

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

The global peptide therapeutics market size was valued at USD 45.43 billion in 2023. It is projected to reach from USD 48.11 ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...